PTGIR and pulmonary arterial hypertension: Apart from the conventionally recommended PAH-specific targeted therapy, namely prostacyclin analogues and prostacyclin receptor agonists, endothelin receptor antagonists, as well as Phosphodiesterase-5 Inhibitors (PDE-5i) and guanylate cyclase stimulators, the role of immunosuppressive agents has also been emphasized in CTD-PAH.6